Want to see HK:6160 full AI Analyst Report?

BeOne Medicines Ltd (6160) Price & Analysis

24 Followers

6160 Stock Chart & Stats

HK$193.20

HK$5.50(5.26%)

At close: Jan 09 4:00 PM EST

HK$193.20

HK$5.50(5.26%)

Day’s Range― - ―

52-Week RangeHK$145.30 - HK$229.40

Previous CloseN/A

Volume1.62M

Average Volume (3M)5.08M

Market Cap

HK$276.05B

Enterprise ValueHK$24.31B

Total Cash (Recent Filing)HK$4.83B

Total Debt (Recent Filing)HK$2.05B

Price to Earnings (P/E)61.0

Beta0.87

Next Earnings

Aug 27, 2026

EPS Estimate

0.97

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.36

Shares Outstanding1,426,363,900

10 Day Avg. Volume3,608,600

30 Day Avg. Volume5,076,742

Financial Highlights & Ratios

PEG Ratio-0.81

Price to Book (P/B)7.49

Price to Sales (P/S)6.10

P/FCF Ratio34.63

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

HK$259.07

Price Target Upside34.09% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering12

EPS Forecast (FY)4.06

Revenue Forecast (FY)HK$50.87B

Bulls Say, Bears Say

Bulls Say

High Margins & Profitability InflectionA durable profitability inflection with ~87% gross margin and positive net income signals strong product economics and pricing power. High margins create resilience to demand volatility, fund R&D and commercialization, and support sustainable operating cash generation even if revenue growth normalizes.

Strong Free Cash Flow GenerationConsistent, substantial free cash flow provides long-term financial flexibility: it can fund late‑stage trials, regulatory submissions, and commercialization without immediate equity dilution. FCF covering most net income indicates earnings quality and supports strategic investment or debt servicing over the next several quarters.

Pivotal Phase 3 Success And Planned SubmissionsA positive, global Phase 3 that met its primary endpoint and prompts regulatory submissions is a structural clinical milestone. If approved, a chemo‑free Brukinsa regimen could expand indications, shift standard of care, and create a durable revenue stream and commercial leverage across oncology markets over multiple years.

Bears Say

Revenue Growth NormalizingA shift from very high historical growth to ~7% TTM suggests the company is moving to steadier expansion. Slower top‑line momentum can limit scalability of R&D investment returns and increases reliance on margin and product launches to drive long-term earnings progression, stressing execution.

Rising LeverageMaterial increase in absolute debt raises financial risk and reduces optionality. Higher leverage limits flexibility for opportunistic M&A or incremental R&D, raises interest exposure, and heightens sensitivity to cash‑flow swings; this matters over multi‑quarter horizons if growth or margins soften.

Cash Conversion Volatility Vs. Accounting ProfitA persistent gap where cash flow covers a fraction of EBIT points to working‑capital or timing effects, reducing the predictability of free cash flow. This can constrain funding for trials or commercialization and make the firm more reliant on external financing during lumpy investment cycles.

BeOne Medicines Ltd News

BeOne Medicines’ Brukinsa shows efficacy in Phase 3 lymphoma trial

BeOne Medicines (ONC) announced positive topline results from the Phase 3 MANGROVE study evaluating foundational BTK inhibitor Brukinsa...

6d ago

ONC

BeOne Medicines announces presentation of Phase 3 data in CLL patients

BeOne Medicines (ONC) announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia...

25d ago

ONC

BeOne Medicines’ BRUKINSA Delivers Pivotal Phase 3 Win in Frontline Mantle Cell Lymphoma

BeOne Medicines Ltd ( ($HK:6160) ) just unveiled an update. BeOne Medicines reported positive topline Phase 3 results...

5d ago

6160

BeOne Medicines Faces RMB446 Million Tax Payment in China, Sees No Material Impact

An announcement from BeOne Medicines Ltd ( ($HK:6160) ) is now available. BeOne Medicines Ltd.’s wholly owned Chinese...

10d ago

6160

BeOne Medicines Grants New Equity Awards Under 2016 Incentive Plan

BeOne Medicines Ltd ( ($HK:6160) ) has shared an announcement. BeOne Medicines has granted new equity awards under...

18d ago

6160

BeOne Medicines Files U.S. Form S-8 to Expand Equity Incentive Plans

An announcement from BeOne Medicines Ltd ( ($HK:6160) ) is now available. BeOne Medicines Ltd., a Swiss-incorporated biopharmaceutical...

24d ago

6160

BeOne Medicines Shareholders Approve All AGM Resolutions and Refresh Board

The latest announcement is out from BeOne Medicines Ltd ( ($HK:6160) ). BeOne Medicines Ltd reported that all...

24d ago

6160

BeOne Medicines Sets Out Board and Committee Structure to Bolster Governance

BeOne Medicines Ltd ( ($HK:6160) ) has shared an announcement. BeOne Medicines has detailed the composition of its...

24d ago

6160

BeOne Medicines Secures Multiple HKEX Rule Waivers to Support Flexible Financing and Partnerships

BeOne Medicines Ltd ( ($HK:6160) ) has shared an update. BeOne Medicines has published an updated company information...

25d ago

6160

BeOne Medicines Formalizes Compensation Committee Charter to Strengthen Governance

BeOne Medicines Ltd ( ($HK:6160) ) has issued an update. BeOne Medicines Ltd. has formalized the role and...

25d ago

6160

BeOne Medicines Grants RSUs to 381 Employees Under Incentive Plan

BeOne Medicines Ltd ( ($HK:6160) ) just unveiled an update. BeOne Medicines has granted 42,648 restricted share units,...

1M ago

6160

BeOne Medicines price target raised to $436 from $425 at RBC Capital

RBC Capital analyst Leonid Timashev raised the firm’s price target on BeOne Medicines (ONC) to $436 from $425...

1M ago

ONC

BeOne Medicines’ combination shows improved survival in adenocarcinoma

BeOne Medicines (ONC) announced data from the HERIZON-GEA-01 trial, published in The New England Journal of Medicine and...

1M ago

ONC

BeOne Medicines price target raised to $367 from $364 at Leerink

Leerink raised the firm’s price target on BeOne Medicines (ONC) to $367 from $364 and keeps an Outperform...

2M ago

ONC

6160 FAQ

What was BeOne Medicines Ltd’s price range in the past 12 months?

BeOne Medicines Ltd lowest stock price was HK$145.30 and its highest was HK$229.40 in the past 12 months.

What is BeOne Medicines Ltd’s market cap?

BeOne Medicines Ltd’s market cap is HK$276.05B.

When is BeOne Medicines Ltd’s upcoming earnings report date?

BeOne Medicines Ltd’s upcoming earnings report date is Aug 27, 2026 which is in 52 days.

How were BeOne Medicines Ltd’s earnings last quarter?

BeOne Medicines Ltd released its earnings results on May 06, 2026. The company reported HK$1.181 earnings per share for the quarter, beating the consensus estimate of HK$0.648 by HK$0.533.

Is BeOne Medicines Ltd overvalued?

According to Wall Street analysts BeOne Medicines Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does BeOne Medicines Ltd pay dividends?

BeOne Medicines Ltd does not currently pay dividends.

What is BeOne Medicines Ltd’s EPS estimate?

BeOne Medicines Ltd’s EPS estimate is 0.97.

How many shares outstanding does BeOne Medicines Ltd have?

BeOne Medicines Ltd has 1,426,363,900 shares outstanding.

What happened to BeOne Medicines Ltd’s price movement after its last earnings report?

BeOne Medicines Ltd reported an EPS of HK$1.181 in its last earnings report, beating expectations of HK$0.648. Following the earnings report the stock price went up 2.941%.

Which hedge fund is a major shareholder of BeOne Medicines Ltd?

Currently, no hedge funds are holding shares in HK:6160

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

BeOne Medicines Ltd Stock Smart Score

Outperform

Fundamentals

Return on Equity

12.04%

Trailing 12-Months

Asset Growth

47.56%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

BeOne Medicines Ltd

BeiGene Ltd. is a global biotechnology enterprise, grounded in scientific research, committed to developing groundbreaking and economical pharmaceutical products. Its core mission is to enhance therapeutic outcomes and broaden patient access to critical medicines across the world. The company was co-founded by Xiao Dong Wang and John V. Oyler on October 28, 2010, and its corporate headquarters are situated in George Town, KY.

BeOne Medicines Ltd (6160) Earnings & Revenues

Historic Earnings Reports

6160 Stock 12 Month Forecast

Average Price Target

HK$259.07

▲(34.09% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"146":"HK$146","219":"HK$219","292":"HK$292","182.5":"HK$182.5","255.5":"HK$255.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":291.9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$291.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":259.06750000000005,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$259.07</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":234,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$234.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[146,182.5,219,255.5,292],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,170.4,179.74615384615385,189.09230769230768,198.43846153846152,207.7846153846154,217.1307692307692,226.47692307692307,235.8230769230769,245.16923076923075,254.5153846153846,263.86153846153843,273.2076923076923,282.5538461538461,{"y":291.9,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,170.4,177.22057692307692,184.04115384615386,190.86173076923077,197.68230769230772,204.50288461538463,211.32346153846157,218.14403846153849,224.96461538461543,231.78519230769234,238.60576923076928,245.4263461538462,252.2469230769231,{"y":259.06750000000005,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,170.4,175.2923076923077,180.1846153846154,185.0769230769231,189.96923076923076,194.86153846153846,199.75384615384615,204.64615384615385,209.53846153846155,214.43076923076922,219.32307692307694,224.2153846153846,229.1076923076923,{"y":234,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":147.8,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":177,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":194.5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":205.2,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":185.8,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":203.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":179.3,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":198.1,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":185,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":185,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":173.6,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":171.5,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":170.4,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >